Brand Name(s):Iressa
Indication:Second-line treatment of locally advanced or metastatic non-small cell lung cancer
Rationale:1
Considered:May-09
Review Date:Dec-20
Comments:
NICE TA374
Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Gefitinib is not recommended for treating locally advanced or metastatic non small cell lung cancer that has progressed after non-targeted chemo in people with tumours that are EGFR-TKmutation-positive
Full document can be found at:http://www.nice.org.uk/guidance/ta374/resources/erlotinib-and-gefitinib-for-treating-nonsmallcell-lung-cancer-that-has-progressed-after-prior-chemotherapy-82602789240517
Dec 2015
…………………………
NICE TA 175
Gefitinib for the second-line treatment of locally advanced or metastatic non-small-cell lung cancer
July 2009